Sign in to use this feature.

Years

Between: -

Subjects

remove_circle_outline
remove_circle_outline
remove_circle_outline

Journals

Article Types

Countries / Regions

Search Results (1)

Search Parameters:
Keywords = microinduction

Order results
Result details
Results per page
Select all
Export citation of selected articles as:
3 pages, 251 KB  
Viewpoint
Buprenorphine Microdosing Cross Tapers: A Time for Change
by Amer Raheemullah, Ori-Michael Benhamou, Jamie Kuo and Anna Lembke
Int. J. Environ. Res. Public Health 2022, 19(24), 16436; https://doi.org/10.3390/ijerph192416436 - 8 Dec 2022
Cited by 6 | Viewed by 3894
Abstract
Buprenorphine is a partial opioid agonist that is Food and Drug Administration (FDA) approved to treat chronic pain and opioid use disorder (OUD). The national prescribing guidelines in the United States (US) recommend that patients transitioning from full opioid agonists to buprenorphine first [...] Read more.
Buprenorphine is a partial opioid agonist that is Food and Drug Administration (FDA) approved to treat chronic pain and opioid use disorder (OUD). The national prescribing guidelines in the United States (US) recommend that patients transitioning from full opioid agonists to buprenorphine first undergo 12 or more hours of active opioid withdrawal, in order to avoid buprenorphine-precipitated opioid withdrawal. This opioid-free period imposes a significant barrier for many patients. Evidence is accumulating that using microdoses of buprenorphine to cross taper from full-agonist opioids to buprenorphine is a safe and effective way to avoid opioid withdrawal and uncontrolled pain. This microdose cross-tapering strategy is already being used across the US. The US prescribing guidelines and buprenorphine training would benefit from acknowledging this new approach. Additionally, to facilitate this strategy, the FDA should approve transdermal buprenorphine formulations for OUD and manufacturers could produce lower dose formulations of sublingual buprenorphine. The time has come for us to embrace buprenorphine microdosing cross tapers as a new standard of care. Full article
(This article belongs to the Special Issue Recent Advances in the Management of Chronic Pain)
Back to TopTop